



EUROPEAN JOURNAL OF CANCER - SUPPLEMENT

AUTHOR INFORMATION PACK

TABLE OF CONTENTS

- **Description** p.1
- **Audience** p.1
- **Abstracting and Indexing** p.1
- **Editorial Board** p.2
- **Guide for Authors** p.4



DESCRIPTION

EJC Supplements is an open access companion journal to the *European Journal of Cancer*. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in *EJC Supplements* are made openly available through the journal's websites.

EJC Supplements will consider for publication the **proceedings** of **scientific symposia**, commissioned thematic issues, and collections of invited articles on preclinical and basic **cancer** research, **translational oncology**, **clinical oncology** and **cancer epidemiology** and **prevention**.

Authors considering the publication of a supplement in *EJC Supplements* are requested to contact the [Editorial Office](#) of the *EJC* to discuss their proposal with the Editor-in-Chief.

EJC Supplements is an official journal of the [European Organisation for Research and Treatment of Cancer \(EORTC\)](#), the [European CanCer Organisation \(ECCO\)](#) and the [European Society of Mastology \(EUSOMA\)](#).

AUDIENCE

Basic and preclinical research oncologists, clinical oncologists (medical, paediatric, radiation, surgical), cancer epidemiologists.

ABSTRACTING AND INDEXING

Biological Sciences
Embase
Elsevier BIOBASE
Pascal Francis
Cambridge Scientific Abstracts
Scopus
Directory of Open Access Journals (DOAJ)

EDITORIAL BOARD

Editor-in-Chief

Alexander M.M. Eggermont, Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands

Editor: Basic Science and Preclinical Research

Ulrich Keilholz, Berlin, Germany

Editor: Epidemiology and Prevention

Jan Willem Coebergh, Oegstgeest, Netherlands

Editor: Tumour Immunotherapy

Aurelin Marabelle, Villejuif, France

Editors: Breast Cancer

Giuseppe Curigliano, Milan, Italy

Suzette Delaloge, Villejuif, France

Editors: Gastrointestinal Cancers

Michel Ducreux, Villejuif, France

Volker Heinemann, Munich, Germany

Editor: Genitourinary Cancers

Karim Fizazi, Villejuif, France

Editor: Head and Neck Cancer

Jean-Pascal Machiels, Bruxelles, Belgium

Editor: Hemato-Oncology

Roch Houot, Rennes, France

Editor: Lung Cancer

Mary O'Brien, Sutton, United Kingdom

Editor: Gynaecological Cancers

Ignace Vergote, Leuven, Belgium

Editor: Melanoma

Dirk Schadendorf, Essen, Germany

Editor: Neuro-oncology

Martin van den Bent, Rotterdam, Netherlands

Editor: Paediatric Oncology

Rob Pieters, Rotterdam, Netherlands

Editorial Office

EJC Editorial Office, Elsevier Ltd, The Boulevard, Langford Lane, Kidlington, OX5 1GB, Oxford, Oxford, UK

Clinical Oncology Editorial Board

A.C.J. van Akkooi, Amsterdam, Netherlands

Richard Baird, Cambridge, United Kingdom

Raffaele Califano, Manchester, United Kingdom

Emiliano Calvo, Madrid, Spain

Fatima Cardoso, Lisboa, Portugal

Elizabeth G. De Vries, Groningen, Netherlands

Adam Dicker, Philadelphia, United States

Reinhard Dummer, Zurich, Switzerland

Sara Erridge, Edinburgh, United Kingdom

Hans Gelderblom, Leiden, Netherlands

Birgit Geoerger, Villejuif, France

John Haanen, Amsterdam, Netherlands

Baktiar Hasan, Brussels, Belgium

Jean-Claude Horiot, Genolier, Switzerland

Dirk Jäger, Heidelberg, Germany

Artur Katz, Sao Paulo, Brazil

Paul Lorigan, Manchester, United Kingdom

Yohann Loriot, Villejuif, France

Christophe Massard, France
Kerrie McDonald, Sydney, Australia
Françoise Meunier, Brussels, Belgium
Tony Mok, Hong Kong, Hong Kong
Do-Hyun Nam, Jongno-gu, South Korea
James Perry, Toronto, Canada
Achim Rody, Lubeck, Germany
Manuela Schmidinger, Vienna, Austria
Jean-Charles Soria, Villejuif, France
Silvia Stacchiotti, Milan, Italy
Cora Sternberg, Roma, Italy
Eric Van Cutsem, Leuven, Belgium
Galina Velikova, Leeds, United Kingdom
Eric Winqvist, London, Canada
Timothy Yap, London, UK

Basic Science and Preclinical Research Editorial Board

Paola Allavena, Rozzano, Milan, Italy
John Anderson, London, England, United Kingdom
Massimo Broggin, Milano, Italy
Christophe Caux
Manuel Esteller, Feixa Llarga, Spain
Enrico Garattini, Milano, Italy
J.M. Irish, Nashville, Tennessee, United States
H.E.K. Kohrt†, Stanford, California, United States
John Lunec, Newcastle, England, United Kingdom
Antonia Maria Müller
Daniel Olive, Marseille, France
Athanasios Papavassiliou, Athens, Greece
Giorgio Parmiani, Milano, Italy
Victoria Sanz-Moreno, London, United Kingdom
Sheila Singh, Hamilton, Ontario, Canada
John Stagg, Quebec, Canada
Amaya Virós, Macclesfield, United Kingdom
Britta Weigelt, New York, United States
Nadia Zaffaroni, Milan, Italy

Epidemiology and Prevention Editorial Board

Phillipe Autier, Écully, France
M. Berwick, NM, United States
N. Bhoo Pathy, Kuala Lumpur, Malaysia
P. Boffetta, New York, United States
Cristina Bosetti, Milano, Italy
E. Crocetti, Florence, Italy
C. Friedenreich, Calgary, Alberta, Canada
G. Gatta, Milan, Italy
I. Lansdorp-Vogelaar, Rotterdam, Netherlands
Marc Maynadié, Dijon, France
Henrik Møller, London, United Kingdom
E. Petridou, Athens, Greece
Lonneke van de Poll-Franse, Eindhoven, Netherlands
Marjanka Schmidt, Amsterdam, Netherlands
Isabelle Soerjomataram, Lyon, France
Esther de Vries, Bogota, Colombia

Paediatric Oncology Editorial Board

Christophe Bergeron, Lyon, France
Eric Bouffet, Toronto, Ontario, Canada
Mitchell Cairo, Valhalla, New York, United States
Guillermo Chantada, Buenos Aires, Argentina
Francois Doz, Paris, France
Andrea Ferrari, Napoli, Italy
Martha Grootenhuis, Amsterdam, Netherlands
Mary van den Heuvel-Eibrink, Rotterdam, Netherlands
Max van Noesel, Rotterdam, Netherlands
Kathy Pritchard-Jones, London, United Kingdom
Lillian Sung, Toronto, Ontario, Canada

GUIDE FOR AUTHORS

General

EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention.

Authors considering the publication of a supplement in *EJC Supplements* are requested to contact the EJC Editorial Office at ejcancer@elsevier.com to discuss their proposal with the Editor-in-Chief. All manuscripts submitted to *EJC Supplements* are peer-reviewed, as outlined below.

Submission checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

Manuscript:

- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

Graphical Abstracts / Highlights files (where applicable)

Supplemental files (where applicable)

Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#).

BEFORE YOU BEGIN

Ethics in publishing

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

Studies in humans and animals

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association](#) (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the [Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals](#) and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms [sex and gender](#) should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARRIVE guidelines](#) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](#), or the National Institutes of Health guide for the care

and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

Declaration of interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](#).

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see '[Multiple, redundant or concurrent publication](#)' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [Crossref Similarity Check](#).

Preprints

Please note that [preprints](#) can be shared anywhere at any time, in line with Elsevier's [sharing policy](#). Sharing your preprints e.g. on a preprint server will not count as prior publication (see '[Multiple, redundant or concurrent publication](#)' for more information).

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Author form

The corresponding author must submit a completed [Author Form](#) with their submission. The form enables the corresponding author to record the contribution of each author and confirms whether ethical approval for the study has been sought, whether funding for the study was provided and whether there are any conflicts of interest. It must be signed by the corresponding author and uploaded to EES with the manuscript.

Acknowledgements

All contributors who do not meet the criteria for authorship as defined by the ICMJE should be listed in an acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance.

Reporting clinical trials

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The [CONSORT checklist and template flow diagram](#) are available online.

Registration of clinical trials

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with [International Committee of Medical Journal Editors](#) recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

Copyright

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (see [more information](#) on this). Permitted third party reuse of open access articles is determined by the author's choice of [user license](#).

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

Elsevier supports responsible sharing

Find out how you can [share your research](#) published in Elsevier journals.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Microarray data

The data should be made available to our readers/reviewers through a MIAME compliant online database or at least a website address.

Biomarkers

Submissions which report biomarkers must comply with the [REMARK Guidelines](#) (McShane L, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK), Eur J Cancer, 2005, 41, 1690-1696.)

Open access

Please visit our [Open Access page](#) for more information.

Open access (OA)

This journal is fully open access; all articles will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

If you need to comply with your funding body policy you can apply for a CC-BY license after your manuscript is accepted for publication.

To provide open access, this journal has a publication fee which needs to be met by the authors or their research funders.

Please contact the Editorial Office for details of the publication fee for this journal.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's Author Services.

PREPARATION

Peer review

This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. [More information on types of peer review.](#)

Article structure

Format

Please write your text in good English with double line-spacing. Original research manuscripts should be no more than 2,500 words in length, with a maximum of 40 references, and review articles should be no more than 3,000 words in length, with an unlimited number of references. Abstracts should not exceed 250 words in length. Manuscripts may be altered to meet the EJC's style.

Manuscripts containing research data generally follow the order: Introduction, Patients (or Materials) and Methods, Results, and Discussion.

Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Highlights

Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: [example Highlights](#).

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

Abstract

The second page should start with the abstract, which should be up to maximum of 250 words and must include the aim of the study, a brief summary of the methods, results and a concluding statement.

Keywords

up to 10 key words from the Medical Subject Headings from Index Medicus.

Formatting of funding sources

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork

Electronic artwork

General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.
- Ensure that color images are accessible to all, including those with impaired color vision.

A detailed [guide on electronic artwork](#) is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) in addition to color reproduction in print. [Further information on the preparation of electronic artwork.](#)

Figure captions

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Data references

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#). Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. [More information on how to remove field codes from different reference management software.](#)

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/ejc-supplements>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

Reference style

Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

Examples:

Reference to a journal publication:

[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. *J Sci Commun* 2010;163:51–9. <https://doi.org/10.1016/j.Sc.2010.00372>.

Reference to a journal publication with an article number:

[2] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. *Heliyon*. 2018;19:e00205. <https://doi.org/10.1016/j.heliyon.2018.e00205>

Reference to a book:

[3] Strunk Jr W, White EB. *The elements of style*. 4th ed. New York: Longman; 2000.

Reference to a chapter in an edited book:

[4] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. *Introduction to the electronic age*, New York: E-Publishing Inc; 2009, p. 281–304.

Reference to a website:

[5] Cancer Research UK. Cancer statistics reports for the UK, <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/>; 2003 [accessed 13 March 2003].

Reference to a dataset:

[dataset] [6] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, *Mendeley Data*, v1; 2015. <https://doi.org/10.17632/xwj98nb39r.1>.

Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (*J Am Med Assoc* 1997;277:927–34) (see also [Samples of Formatted References](#)).

Supplementary material

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Research data

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

Data linking

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

Mendeley Data

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

Data statement

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

AFTER ACCEPTANCE

Online proof correction

To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints

The corresponding author will be notified and receive a link to the published version of the open access article on [ScienceDirect](#). This link is in the form of an article DOI link which can be shared via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Author Services](#).

AUTHOR INQUIRIES

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2018 Elsevier | <https://www.elsevier.com>